Shandong Sinobioway Biomedicine Past Earnings Performance
Past criteria checks 0/6
Shandong Sinobioway Biomedicine's earnings have been declining at an average annual rate of -9.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 9.4% per year.
Key information
-9.8%
Earnings growth rate
-9.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -9.4% |
| Return on equity | -13.0% |
| Net Margin | -77.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shandong Sinobioway Biomedicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 438 | -339 | 458 | 58 |
| 31 Dec 23 | 430 | -332 | 453 | 60 |
| 30 Sep 23 | 420 | -49 | 416 | 46 |
| 30 Jun 23 | 379 | -92 | 417 | 44 |
| 31 Mar 23 | 345 | -38 | 411 | 30 |
| 31 Dec 22 | 357 | -15 | 423 | 27 |
| 30 Sep 22 | 362 | -12 | 439 | 37 |
| 30 Jun 22 | 366 | 157 | 426 | 33 |
| 31 Mar 22 | 408 | 248 | 474 | 35 |
| 01 Jan 22 | 403 | 271 | 476 | 38 |
| 30 Sep 21 | 402 | 258 | 485 | 33 |
| 30 Jun 21 | 365 | 34 | 465 | 43 |
| 31 Mar 21 | 258 | -109 | 416 | 45 |
| 31 Dec 20 | 277 | -196 | 426 | 49 |
| 30 Sep 20 | 324 | -92 | 473 | 51 |
| 30 Jun 20 | 404 | -55 | 510 | 47 |
| 31 Mar 20 | 543 | 13 | 540 | 57 |
| 31 Dec 19 | 568 | 63 | 543 | 55 |
| 30 Sep 19 | 606 | -67 | 576 | 63 |
| 30 Jun 19 | 670 | -84 | 585 | 63 |
| 31 Mar 19 | 644 | -191 | 531 | 49 |
| 31 Dec 18 | 665 | -104 | 542 | 46 |
| 30 Sep 18 | 894 | 129 | 473 | 35 |
| 30 Jun 18 | 926 | 217 | 433 | 53 |
| 31 Mar 18 | 1,039 | 394 | 458 | 46 |
| 31 Dec 17 | 1,162 | 388 | 471 | 39 |
| 30 Sep 17 | 1,151 | 420 | 498 | 28 |
| 30 Jun 17 | 1,238 | 442 | 538 | 0 |
| 31 Mar 17 | 1,278 | 417 | 535 | 0 |
| 31 Dec 16 | 1,265 | 418 | 533 | 0 |
| 30 Sep 16 | 1,230 | 374 | 524 | 0 |
| 30 Jun 16 | 1,095 | 316 | 487 | 0 |
| 31 Mar 16 | 956 | 287 | 448 | 0 |
| 31 Dec 15 | 858 | 250 | 435 | 0 |
| 30 Sep 15 | 707 | 205 | 392 | 0 |
| 31 Dec 14 | 624 | 225 | 350 | 0 |
| 31 Dec 13 | 401 | 109 | 266 | 0 |
Quality Earnings: 002581 is currently unprofitable.
Growing Profit Margin: 002581 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002581 is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare 002581's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002581 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 002581 has a negative Return on Equity (-13.03%), as it is currently unprofitable.